Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
CTI BioPharma
Study ID
NCT00054197
Phase
PHASE3
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether polyglutamate paclitaxel is more effective than gemcitabine or vinorelbine in treating non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel with that of gemcitabine or vinorelbine in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.

Key Dates

Start date
Jan 31, 2003
Status verified
Oct 2020
Primary completion
Oct 31, 2004
Completion
Oct 31, 2004

Study Design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Locations (10)

FacilityCityStateZIPSite coordinators
Cooper Green HospitalBirminghamAlabama35233-
Medical Oncology/HematologyGilroyCalifornia95020-
Northwest Oncology and Hematology AssociatesCoral SpringsFlorida33065-
Midwest Cancer Research Group, IncorporatedSkokieIllinois60077-
Medschool Associates NorthRenoNevada89502-
New York Oncology Hematology, P.C. - LathamLathamNew York12110-0610-
Clinical Research ServicesBismarckNorth Dakota58501-
Charleston Hematology-Oncology, P.A.CharlestonSouth Carolina29403-
Western Washington Medical GroupEverettWashington98201-
Western Washington Oncology, IncorporatedOlympiaWashington98502-

Find similar trials in Birmingham, AL

By condition

Related Studies